Prevention of early mortality by presumptive tuberculosis therapy study: An open label, randomized controlled trial

Y.C. Manabe, W. Worodria, F. Van Leth, H. Mayanja-Kizza, A.N. Traore, J. Ferro, N. Pakker, M. Frank, M.P. Grobusch, R. Colebunders, F. Cobelens

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Copyright © 2016 by The American Society of Tropical Medicine and Hygiene.Early mortality after initiation of antiretroviral therapy (ART) occurs in 9-39% of patients in sub-Saharan Africa. A significant proportion of deaths are attributable to tuberculosis (TB). Low baseline CD4 T-cell count and low body mass index (BMI) are strongly associated with early mortality. We hypothesized that initiation of ART concurrent with presumptive anti-TB chemotherapy in high-risk patients would reduce mortality within the first 6 months by treating unrecognized TB. From October 2011 to December 2012, ART-naive, smear-negative participants with a CD4 T-cell count < 50 cells/?L and BMI < 18 kg/m2 were randomly assigned to undergo either empiric four-drug anti-TB treatment followed 2 weeks later by efavirenz-based ART (N = 23) (ART + TB) or ART only (N = 20). This open-label, 1:1 randomized, controlled trial took place in Uganda, Mozambique, and Gabon and was stopped prematurely by the sponsor for slow recruitment. Overall, the 43 participants had a median CD4 of 22 (interquartile range [IQR]: 9-35) cells/?L and a median BMI of 17.5 (IQR: 16.6-18.0) kg/m2. The mortality was 14% (95% confidence interval [CI]: 5.3-27.9); two (10.0%) participants (ART-only group), and four (17.4%; ART + TB group). The associated hazard ratio (HR) for all-cause mortality was 1.6 (95% CI: 0.30-8.90). Despite limited enrollment, the study did not suggest that empiric TB treatment in severely immunosuppressed patients with low BMI decreased mortality and, had an HR in the opposite direction than expected. Notably, two participants in the ART + TB group died with autopsy-confirmed drug-induced hepatotoxicity. Improved TB diagnostics sensitive in immunosuppressed patients presenting late to care are urgently needed for more targeted interventions.
Original languageEnglish
Pages (from-to)1265-1271
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume95
Issue number6
DOIs
Publication statusPublished - 1 Dec 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Prevention of early mortality by presumptive tuberculosis therapy study: An open label, randomized controlled trial'. Together they form a unique fingerprint.

Cite this